LivaNova (LIVN) Set to Announce Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is scheduled to be announcing its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.47 per share for the quarter. LivaNova has set its FY 2024 guidance at 2.950-3.050 EPS and its FY24 guidance at $2.95-3.05 EPS.Parties interested in registering for the company’s conference call can do so using this link.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. During the same period last year, the business earned $0.81 earnings per share. LivaNova’s revenue was up 12.8% compared to the same quarter last year. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Trading Up 1.9 %

NASDAQ LIVN opened at $55.02 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. LivaNova has a one year low of $42.75 and a one year high of $59.86. The firm has a 50 day simple moving average of $53.77 and a 200-day simple moving average of $50.55. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 171.94 and a beta of 0.89.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LIVN. Mizuho reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and issued a $72.00 price target on shares of LivaNova in a research note on Wednesday, March 20th. Barclays lifted their target price on LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. StockNews.com downgraded LivaNova from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Finally, Robert W. Baird lifted their target price on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $64.40.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.